Clinical Handbook of Psychotropic Drugs

Abstract

Quick and comprehensive information on psychotropic drugs for adults.

• Accurate and up-to-date

• Comparison charts help decision-making

• Icons and full color

• Available in print and online

• Downloadable patient info sheets

More about this book

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

• Independent, unbiased, up-to-date

• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options

• Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug

• Potential interactions and side effects summarized in comparison charts

• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek

• Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition

• Neuroscience-based nomenclature – added to product availability tables

• Antidepressants chapter includes new section on GABA _A receptor positive modulator (brexanolone IV injection; trade name Zulresso)

• Also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies

• Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment

• Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised

• New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta(lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)